Advertisement

Pharmaceutical Chemistry Journal

, Volume 42, Issue 3, pp 145–149 | Cite as

Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate)

  • E. V. Shipulo
  • I. I. Lyubimov
  • O. O. Maksimenko
  • L. V. Vanchugova
  • E. A. Oganesyan
  • P. G. Sveshnikov
  • S. F. Biketov
  • E. S. Severin
  • L. B. Heifets
  • S. E. Gel’perina
Article

Abstract

A nanosomal formulation of moxifloxacin has been prepared by anionic polymerization of poly(butyl-2-cyanoacrylate) in the presence of the drug. The poly(butyl-2-cyanoacrylate) nanoparticles absorb effectively moxifloxacin with a high total content and have a considerable capacity (> 45%). The influence of reaction parameters such as pH and drug-to-polymer ratio on the nanoparticle characteristics has been studied. The efficacy of the novel formulation has been evaluated in mice infected with M. tuberculosis. It is shown that the efficacy of the proposed nanosomal formulation for i.v. administration evaluated by a decrease in the lung mycobacteria count is more than twice that of a reference preparation.

Keywords

Moxifloxacin Pefloxacin Anionic Polymerization Average Nanoparticle Size Mannite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Pinto-Alphandary, A. Andremont, and P. Couvreur, Int. J. Antimicrob. Agents, 13, No. 3, 155–168 (2000).PubMedCrossRefGoogle Scholar
  2. 2.
    R. Pandey and G. K. Khuller, Indian J. Exp. Biol., 44, No. 5, 357–366 (2006).PubMedGoogle Scholar
  3. 3.
    R. Pandey, S. Sharma, and G. K. Khuller, Tuberculosis (Edinb.), 85, No. 5–6, 415–420 (2005).CrossRefGoogle Scholar
  4. 4.
    R. Rastogi, Y. Sultana, A. Ali, et al., Curr. Drug Delivery, 3, No. 1, 121–128 (2006).CrossRefGoogle Scholar
  5. 5.
    S. Gelperina, K. Kisich, M. D. Iseman, et al., Am. J. Respir. Crit. Care Med., 15, 172, No. 12, 1487–1490 (2005).CrossRefGoogle Scholar
  6. 6.
    J. Kreuter, ed., “Nanoparticles,” in: Colloidal Drug Delivery Systems, Marcel Dekker, New York (1994), pp. 291–342.Google Scholar
  7. 7.
    C. Vautheir, C. Dubernet, E. Fattal, et al., Adv. Drug Delivery Rev., 55, No. 4, 519–548 (2003).CrossRefGoogle Scholar
  8. 8.
    E. Fattal, M. Youssef, P. Couvreur, et al., Antimicrob. Agents Chemother., 33, No. 9, 1540–1543 (1989).PubMedGoogle Scholar
  9. 9.
    I. N. Skidan, S. E. Gel(perina, S. E. Severin, et al., Antibiot. Khimioter., 48, No. 1, 23–26 (2003).PubMedGoogle Scholar
  10. 10.
    M. Youssef, E. Fattal, M.-J. Alonso, et al., Antimicrob. Agents Chemother., 32, No. 8, 1204–1207 (1988).PubMedGoogle Scholar
  11. 11.
    E. A. Oganesyan, A. P. Bud(ko, Yu. V. Stukalov, et al., Antibiot. Khimioter., 50, No. 8–9, 15–19 (2005).Google Scholar
  12. 12.
    F. Fawaz, F. Bonini, J. Maugein, et al., Int. J. Pharm., 168, 225–259 (1998).CrossRefGoogle Scholar
  13. 13.
    M. I. Perel(man, G. B. Sokolova, G. N. Mozhokhina, et al., Antibiot. Khimioter., 49, No. 6, 20–24 (2004).Google Scholar
  14. 14.
    L. S. Strachunskii and V. A. Krechikov, Klin. Mikrobiol. Antimicrob. Khimioter., 3, 3–40 (2001).Google Scholar
  15. 15.
    S. J. Douglas, L. Illum, S. S. Davis, et al., J. Colloid Interface Sci., 101, No. 1, 149–175 (1984).CrossRefGoogle Scholar
  16. 16.
    F. Fawaz, M. Guyot, A. M. Lagueny, et al., Int. J. Pharm., 154, 191–203 (1997).CrossRefGoogle Scholar
  17. 17.
    M. Fresta, G. Puglisi, G. Giammona, et al., J. Pharm. Sci., 84, No. 7, 895–901 (1995).PubMedCrossRefGoogle Scholar
  18. 18.
    C. M. Shoen, M. S. DeStefano, M. R. Sklaney, et al., Int. J. Antimicrob. Agents, 53, No. 4, 641–645 (2004).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2008

Authors and Affiliations

  • E. V. Shipulo
    • 1
  • I. I. Lyubimov
    • 2
  • O. O. Maksimenko
    • 1
  • L. V. Vanchugova
    • 1
  • E. A. Oganesyan
    • 1
  • P. G. Sveshnikov
    • 1
  • S. F. Biketov
    • 2
  • E. S. Severin
    • 1
  • L. B. Heifets
    • 3
  • S. E. Gel’perina
    • 1
  1. 1.Research Center for Molecular Diganostics and TherapyMoscowRussia
  2. 2.State Scientific Center for Applied Microbiology and BiotechnologyObolensk, Moscow OblastRussia
  3. 3.National Jewish Medical Research CenterDenverUSA

Personalised recommendations